FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124328376> ?p ?o ?g. }

• W3124328376 endingPage "114" @default.
• W3124328376 startingPage "114" @default.
• W3124328376 abstract "Background: Enisamium iodide (EI) is a Russian drug whose molecule was developed in the Institute of Pharmacology and Toxicology of Ukraine as an anti-inflammatory and antipyretic agent. Later, other properties of EI were found: inhibition of the influenza virus hemagglutinin, increasing the production of interferon-γ, level of Th1, blood antioxidant activity, inhibition TNF-α and other pro-inflammatory cytokines, activation of macrophages and lysozyme activity. The aim of study was to evaluate the efficacy of antiviral therapy with EI in out-patient patients with influenza and influenza-like illnesses (ILI) without risk factors for severe course of disease. Methods and materials: 124 patients aged 18–55 years with influenza and ILI within 6–48 h of symptoms onset were randomized into 2 groups. 1st group (n = 66) was treated with EI 500 mg tid 5 days, 2nd group (n = 63) received placebo according to the same scheme. In the 1nd group the proportion between influenza and other respiratory viruses was 32.2%: 67.8%, in the 2nd group 31.7%: 68.3%, accordingly. Duration of disease and main clinical symptoms, frequency of complications and speed of the virus elimination from the nasopharynx were estimated. Results: The number of cases with complete recovery within 96 h was 56 (84.8% ± 4.2%) in 1st group and 44 (69.8% ± 5.8%) in 2nd group (p = 0.047). The duration of fever was 68.0 ± 2.8 h in 1th group and 77.1 ± 2.9 h in 2nd group (p = 0.044), muscle pain – 52.3 ± 2.3 and 60.6 ± 2.6 h (p = 0.041), headache-52.1 ± 2.6 and 65.1 ± 2.5 h (p = 0.032), weakness – 75.5 ± 2.3 and 90.4 ± 2.5 h (p = 0.001), accordingly. On the 4th day of treatment the viruses were isolated in 37.8 ± 5.9% of cases in the 1st group and 57.1 ± 6.2% in 2nd group; p = 0.048. Bacterial complications were observed in 3.0 ± 2.1% and 12.6 ± 4.2% accordingly, p = 0.048. Conclusion: The study is demonstrated the effectiveness of EI in the treatment of influenza and ILI in adult outpatient patients. The antiviral and anti-inflammatory effects of the drug, which was administered within 48 h of the symptoms onset were demonstrated by a more rapid reduction of clinical symptoms, frequency of bacterial complications and reduction in the time of virus elimination. Continuation of EI clinical trials are necessary for more full evaluation of its effectiveness." @default.
• W3124328376 created "2021-02-01" @default.
• W3124328376 creator A5023708009 @default.
• W3124328376 creator A5043778073 @default.
• W3124328376 creator A5059199072 @default.
• W3124328376 creator A5063066967 @default.
• W3124328376 creator A5072112132 @default.
• W3124328376 creator A5072282768 @default.
• W3124328376 date "2020-12-01" @default.
• W3124328376 modified "2023-10-12" @default.
• W3124328376 title "Perspectives of treatment of influenza and influenza-like illnesses with Enisamium yodide – Antiviral with anti-inflammatory effect" @default.
• W3124328376 doi "https://doi.org/10.1016/j.ijid.2020.09.315" @default.
• W3124328376 hasPublicationYear "2020" @default.
• W3124328376 type Work @default.
• W3124328376 sameAs 3124328376 @default.
• W3124328376 citedByCount "0" @default.
• W3124328376 crossrefType "journal-article" @default.
• W3124328376 hasAuthorship W3124328376A5023708009 @default.
• W3124328376 hasAuthorship W3124328376A5043778073 @default.
• W3124328376 hasAuthorship W3124328376A5059199072 @default.
• W3124328376 hasAuthorship W3124328376A5063066967 @default.
• W3124328376 hasAuthorship W3124328376A5072112132 @default.
• W3124328376 hasAuthorship W3124328376A5072282768 @default.
• W3124328376 hasBestOaLocation W31243283761 @default.
• W3124328376 hasConcept C126322002 @default.
• W3124328376 hasConcept C142724271 @default.
• W3124328376 hasConcept C203014093 @default.
• W3124328376 hasConcept C204787440 @default.
• W3124328376 hasConcept C2522874641 @default.
• W3124328376 hasConcept C27081682 @default.
• W3124328376 hasConcept C2777546802 @default.
• W3124328376 hasConcept C2779252780 @default.
• W3124328376 hasConcept C2780820201 @default.
• W3124328376 hasConcept C71924100 @default.
• W3124328376 hasConcept C90924648 @default.
• W3124328376 hasConcept C98274493 @default.
• W3124328376 hasConceptScore W3124328376C126322002 @default.
• W3124328376 hasConceptScore W3124328376C142724271 @default.
• W3124328376 hasConceptScore W3124328376C203014093 @default.
• W3124328376 hasConceptScore W3124328376C204787440 @default.
• W3124328376 hasConceptScore W3124328376C2522874641 @default.
• W3124328376 hasConceptScore W3124328376C27081682 @default.
• W3124328376 hasConceptScore W3124328376C2777546802 @default.
• W3124328376 hasConceptScore W3124328376C2779252780 @default.
• W3124328376 hasConceptScore W3124328376C2780820201 @default.
• W3124328376 hasConceptScore W3124328376C71924100 @default.
• W3124328376 hasConceptScore W3124328376C90924648 @default.
• W3124328376 hasConceptScore W3124328376C98274493 @default.
• W3124328376 hasLocation W31243283761 @default.
• W3124328376 hasOpenAccess W3124328376 @default.
• W3124328376 hasPrimaryLocation W31243283761 @default.
• W3124328376 hasRelatedWork W158170765 @default.
• W3124328376 hasRelatedWork W1973700122 @default.
• W3124328376 hasRelatedWork W2012488790 @default.
• W3124328376 hasRelatedWork W2070968935 @default.
• W3124328376 hasRelatedWork W2134606986 @default.
• W3124328376 hasRelatedWork W2152952577 @default.
• W3124328376 hasRelatedWork W2166345995 @default.
• W3124328376 hasRelatedWork W2323485108 @default.
• W3124328376 hasRelatedWork W2591705055 @default.
• W3124328376 hasRelatedWork W66115843 @default.
• W3124328376 hasVolume "101" @default.
• W3124328376 isParatext "false" @default.
• W3124328376 isRetracted "false" @default.
• W3124328376 magId "3124328376" @default.
• W3124328376 workType "article" @default.